Ginkgo Bioworks Holdings, Inc. Class A DNA

BOSTON, September 16, 2026--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data.

BOSTON, September 10, 2026--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a m

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.

Moby summary of Ginkgo Bioworks Holdings, Inc.'s Q2 2026 earnings call

Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management. The launch builds on the three companies' strategic partnership

Ginkgo Bioworks Holdings Inc (NYSE:DNA) is one of the best small cap agriculture stocks to buy now. Ginkgo Bioworks is developing an autonomous lab that it calls Nebula. Biotech companies can use this lab to develop biological solutions for farms as alternatives to traditional chemicals and fertilizers. With Nebula, Ginkgo Bioworks offers robot-powered laboratories that […]

One thing we could say about the analysts on Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) - they aren't optimistic...

The reset in Ginkgo Bioworks Holdings’ price target from US$9 to US$5 sits against an unchanged fair value estimate of US$8.67 per share, putting a sharper spotlight on how analysts are framing risk and timing. Some see the lower target as a cleaner reset after the biosecurity divestiture, while others treat it as a clear signal that expectations around monetizing autonomous labs are being pulled back. Keep reading to see how you can track this evolving story and which checkpoints may matter...